Onconetix, Inc. (ONCO)
1.02
+0.28
(+38.02%)
USD |
NASDAQ |
Sep 04, 16:00
0.813
-0.21
(-20.29%)
After-Hours: 20:00
Onconetix SG&A Expense (TTM) : 8.131M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.131M |
| March 31, 2026 | 7.409M |
| December 31, 2025 | 7.044M |
| September 30, 2025 | 8.171M |
| June 30, 2025 | 8.472M |
| March 31, 2025 | 9.169M |
| December 31, 2024 | 11.23M |
| September 30, 2024 | 14.83M |
| June 30, 2024 | 16.46M |
| March 31, 2024 | 16.54M |
| December 31, 2023 | 14.57M |
| September 30, 2023 | 10.38M |
| Date | Value |
|---|---|
| June 30, 2023 | 8.803M |
| March 31, 2023 | 9.502M |
| December 31, 2022 | 9.352M |
| September 30, 2022 | 8.077M |
| June 30, 2022 | 6.209M |
| March 31, 2022 | 3.445M |
| December 31, 2021 | 2.133M |
| September 30, 2021 | 1.601M |
| March 31, 2021 | 0.7749M |
| December 31, 2020 | 0.5374M |
| September 30, 2020 | 0.2336M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| BridgeBio Pharma, Inc. | 645.86M |
| Aprea Therapeutics, Inc. | 6.507M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |